600252.SHG Guangxi Wuzhou Zhongheng Group Co Ltd
- Market cap
- CNY 7.13B
- P/E
- -
- P/B
- 1.33x
- ROE
- -1.0%
- Dividend yield
- 0.78%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600252.SHG undervalued?
Graham numberThe Graham number of Guangxi Wuzhou Zhongheng Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangxi Wuzhou Zhongheng Group Co Ltd fundamental analysis
No fundamental analysis for Guangxi Wuzhou Zhongheng Group Co Ltd yet.
Guangxi Wuzhou Zhongheng Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangxi Wuzhou Zhongheng Group Co Ltd
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics, ophth…
Full company profileGuangxi Wuzhou Zhongheng Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangxi Wuzhou Zhongheng Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.67B | 2.05B | 3.30B | 3.81B | 3.68B | 3.16B | 2.71B | 3.10B | 2.27B | 1.75B | 1.33B |
| Gross Profit | 1.21B | 1.66B | 2.95B | 3.19B | 2.85B | 2.32B | 1.61B | 1.87B | 936M | 771M | 654M |
| Operating Income | 618M | 774M | 707M | 907M | 347M | 178M | 43.4M | 133M | -517M | -178M | -34.4M |
| EBITDA | 712M | 760M | 630M | 720M | 505M | 249M | 166M | 182M | -33.4M | -306M | 2.02M |
| Net Income | 489M | 605M | 613M | 745M | 563M | 307M | 79.0M | 84.3M | -377M | -357M | -50.6M |
| EPS | 0.14 | 0.17 | 0.18 | 0.22 | 0.16 | 0.09 | 0.02 | 0.02 | -0.11 | -0.11 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 6.49B | 6.86B | 7.24B | 7.84B | 12.0B | 11.9B | 11.8B | 11.7B | 11.0B | 10.1B | 8.70B |
| Total Liabilities | 1.16B | 1.27B | 1.31B | 1.44B | 3.75B | 3.20B | 3.46B | 3.39B | 3.46B | 3.32B | 2.17B |
| Shareholders' Equity | 5.32B | 5.59B | 5.93B | 6.39B | 6.85B | 6.62B | 6.52B | 6.57B | 6.02B | 5.37B | 5.18B |
| Cash & Short-term Investments | 2.31B | 1.70B | 2.36B | 2.75B | 3.56B | 4.46B | 4.20B | 3.59B | 4.15B | 3.41B | 2.14B |
| Total Debt | - | - | 6.77M | 111M | 1.76B | 1.56B | 1.96B | 1.58B | 1.78B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.50B | 893M | 853M | 654M | 657M | -76.7M | -170M | 484M | 477M | -18.9M | - |
| Capital Expenditure | 89.2M | 178M | 211M | 160M | 166M | 286M | 202M | 167M | 199M | 101M | 48.2M |
| Free Cash Flow | 1.41B | 715M | 643M | 494M | 491M | -362M | -372M | 236M | 279M | -120M | -48.9M |
| Ratios | |||||||||||
| ROE | 9.2% | 10.8% | 10.3% | 11.7% | 8.2% | 4.6% | 1.2% | 1.3% | -6.3% | -6.7% | -1.0% |
| ROA | 7.5% | 8.8% | 8.5% | 9.5% | 4.7% | 2.6% | 0.7% | 0.7% | -3.4% | -3.5% | -0.6% |
| Net Profit Margin | 29.3% | 29.5% | 18.6% | 19.5% | 15.3% | 9.7% | 2.9% | 2.7% | -16.6% | -20.4% | -3.8% |
| Debt to Equity | - | - | 0.00x | 0.02x | 0.26x | 0.23x | 0.30x | 0.24x | 0.29x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangxi Wuzhou Zhongheng Group Co Ltd dividends
- Dividend yield
- 0.78%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 24, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 55.3M | 0.02 | - |
| 2024 | CNY 90.9M | 0.03 | - |
| 2023 | CNY 107M | 0.03 | 127.4% |
| 2022 | CNY 92.5M | 0.03 | 117.0% |
| 2021 | CNY 295M | 0.09 | 96.0% |
| 2020 | CNY 206M | 0.06 | 36.5% |
| 2019 | CNY 209M | 0.06 | 28.0% |
| 2018 | CNY 209M | 0.06 | 34.0% |
| 2017 | CNY 156M | 0.04 | 25.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Sep 16, 2015.
Who owns Guangxi Wuzhou Zhongheng Group Co Ltd
- Insiders 33.57%
- Institutions 1.21%
- Public & others 65.21%
- Shares outstanding 3.18B
- Free float 2.21B
Guangxi Wuzhou Zhongheng Group Co Ltd company profile
- Company name
- Guangxi Wuzhou Zhongheng Group Co Ltd
- Ticker
- 600252.SHG
- ISIN
- CNE0000015F9
- Exchange
- Shanghai Stock Exchange
- Listed since
- Oct 27, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,843
- Fiscal year end
- December
- Address
- No. 1 Industrial Avenue, Wuzhou, China, 543000
- Phone
- 86 77 1274 2275
- Website
- wz-zhongheng.com
About Guangxi Wuzhou Zhongheng Group Co Ltd
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, and other healthcare applications. It also provides clindamycin hydrochloride injection, esomeprazole sodium injection, esomeprazole magnesium enteric-coated capsules, cefoperazone dry suspension, naloxone hydrochloride injection, and fludarabine phosphate injection. Further, the company is involved in production of oral care, clothing care, and home care products, including toothpaste; health food business; pharmaceutical distribution; project investment and management; real estate development and operation; and cosmetic products businesses. Guangxi Wuzhou Zhongheng Group Co., Ltd was founded in 1993 and is based in Wuzhou, China.
Guangxi Wuzhou Zhongheng Group Co Ltd management
8- Mr. Hui GeFinancial Officer · born 1979
- Mr. Ming ChenDeputy GM & Chief Technology Officer · born 1967
- Mr. Hai Run WangDeputy GM, General Counsel, Secretary, Chief Compliance Officer & Director · born 1988
- Mr. Weimin PengDeputy General Manager & Chief Quality Officer · born 1968
- Mr. Xiangyong WangDeputy General Manager · born 1970
- Mr. Tian Jiao WangDeputy General Manager · born 1989
- Peng LiAccounting Supervisor
- Ms. Meifang JiangDeputy General Manager · born 1989